Iovance (IOVA) Form 3: CFO Corleen Roche reports no holdings

Iovance Biotherapeutics (IOVA) filed an initial Form 3 reporting that Corleen Roche joined the company as Chief Financial Officer on 08/06/2025.

Rhea-AI Filing Summary

Iovance Biotherapeutics (IOVA) filed an initial Form 3 reporting that Corleen Roche joined the company as Chief Financial Officer on 08/06/2025. The filing states that Ms. Roche does not beneficially own any securities of the issuer as of that date. The form is an initial statutory disclosure under Section 16 to record the reporting person's relationship and any ownership or derivative positions.

Positive

• Appointment recorded of Corleen Roche as Chief Financial Officer on 08/06/2025
• No current insider holdings reported, reducing immediate conflict-of-interest disclosure complexity

Negative

• None.

Insights

Corporate Governance Analyst

New CFO disclosed with no current equity holdings.

The filing records that Corleen Roche became Chief Financial Officer on 08/06/2025 and has no direct or indirect beneficial ownership reported at filing. This is a routine Section 16 disclosure triggered by the officer appointment.

The main dependency is whether equity grants or purchases follow customary onboarding grants; any future awards will require additional Section 16 filings. Monitor subsequent Form 4 filings for grants, exercises, or purchases within the next weeks to months.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did IOV A's Form 3 filed by Corleen Roche disclose?

The Form 3 discloses that Corleen Roche became Chief Financial Officer on 08/06/2025 and does not beneficially own any securities of IOV A as of that date.

Does the Form 3 report any stock or option grants for Corleen Roche (IOVA)?

No. The filing explicitly states no securities are beneficially owned; there are no derivative or non-derivative holdings listed.

When should investors expect additional filings after this Form 3 for IOVA?

Investors should watch for subsequent Form 4 filings, which disclose any stock grants, option awards, purchases, or sales following the appointment; timing depends on when awards are granted or transactions occur.

Why is a Form 3 filed when an executive joins a company (IOVA)?

A Form 3 is the required initial statement under Section 16 to disclose a reporting person's relationship to the issuer and any existing ownership; it establishes the reporting baseline for future transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/08/2025 - 04:05 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Roche Corleen M.

(Last) (First) (Middle)

C/O IOVANCE BIOTHERAPEUTICS, INC.

825 INDUSTRIAL ROAD, SUITE 100

(Street)

SAN CARLOS CA 94070

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/06/2025

3. Issuer Name and Ticker or Trading Symbol
IOVANCE BIOTHERAPEUTICS, INC. [ IOVA ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

1. On August 6, 2025, Corleen Roche joined Iovance Biotherapeutics, Inc. as its Chief Financial Officer.

No securities are beneficially owned.

	/s/ Corleen Roche	08/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.